Plain language summary of the MajesTEC-1 study of teclistamab for the treatment of people with relapsed or refractory multiple myeloma
Year: 2023
Type: article
Abstract: WHAT IS THIS SUMMARY ABOUT?: This is a summary of a phase 1-2 clinical trial called MajesTEC-1. This trial tested the cancer drug teclistamab in people with relapsed or refractory multiple myeloma, a cancer that forms in a certain type of white blood cells known as plasma cells. Most participants who took part in the study had at least 3 prior treatments for multiple myeloma before their cancer came back. HOW WAS THE STUDY IN THIS SUMMARY CONDUCTED?: A total of 165 participants from 9 countries were included in this study. All participants were given teclistamab once per week and monitored for side effects. Once participants started taking teclistamab, they were checked regularly to monitor if their cancer had no change, improved (responded to treatment), or worsened or spread (known as disease progression). WHAT WERE THE RESULTS OF THE STUDY?: After approximately 14.1 months of follow-up (from 2020 to 2021), 63% of participants who were given teclistamab had a decrease in myeloma burden, meaning that they responded to treatment with teclistamab. Participants who responded to teclistamab lived without their myeloma coming back for approximately 18.4 months. The most common side effects were infections, cytokine release syndrome, abnormally low white and red blood cell counts (neutropenia, lymphopenia, and anemia), and low platelet cell counts (thrombocytopenia). Approximately 65% of participants experienced serious side effects. WHAT DO THE RESULTS OF THIS STUDY MEAN?: NCT03145181, NCT04557098 (ClinicalTrials.gov).
Source: Future Oncology
Authors: Philippe Moreau, Niels WCJ van de Donk, Hareth Nahi, Albert Oriol, Ajay K Nooka, Thomas Martin, Laura Rosinol, Lionel Karlin, Lotfi Benboubker, Maria-Victoria Mateos, Rakesh Popat, Joaquín Martínez-López, Surbhi Sidana, Michel Delforge, Lixia Pei, Danielle Trancucci, Yunsi Olyslager, Clarissa Uhlar, Tara Stephenson, Rian Van Rampelbergh, Arnob Banerjee, Rachel Kobos, Saad Z Usmani
Institutions: Amsterdam University Medical Centers, Cancer Center Amsterdam, Vrije Universiteit Amsterdam, Amsterdam UMC Location Vrije Universiteit Amsterdam, Karolinska University Hospital, Josep Carreras Leukaemia Research Institute, Institut Català d'Oncologia, Emory University, Winship Cancer Institute, University of California, San Francisco, Universitat de Barcelona, Hôpital Lyon Sud, Centre Hospitalier Universitaire de Tours, Hôpital Bretonneau, Instituto de Investigación Biomédica de Salamanca, Centro de Investigación del Cáncer, University College London Hospitals NHS Foundation Trust, National Institute for Health and Care Research, Universidad Complutense de Madrid, Spanish National Cancer Research Centre, Hospital Universitario 12 De Octubre, Centro de Investigación Biomédica en Red de Cáncer, Stanford Medicine, Stanford University, KU Leuven, Janssen Research & Development (United States), Janssen (Belgium), Memorial Sloan Kettering Cancer Center, Levine Cancer Institute
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Funder: Janssen Research and Development
OpenAlex ID: W4367834486